On Demand: Better Together: How Pharmacy and Cardiology Partnerships Elevate the Transthyretin Amyloidosis Care Delivery Journey-Webinar Recording

Video Transcription

Video Summary

The webinar, sponsored by Alnylam and hosted by MedAxiom, focused on how stronger pharmacy–cardiology partnerships can improve the care journey for patients with transthyretin amyloidosis (ATTR), a rare, progressive disease that is often underdiagnosed and undertreated. Speakers highlighted how ATTR can present as cardiomyopathy, polyneuropathy, or both, typically in older adults, and emphasized that despite an estimated 150,000 U.S. patients with cardiac amyloid, only a small fraction are appropriately treated—driving worse outcomes and higher hospitalization costs.<br /><br />Survey findings showed fragmented patient identification, limited standardized care pathways, and weak cross-specialty coordination among cardiology, neurology, and pharmacy. Panelists described how embedding pharmacists in cardiology clinics supports earlier recognition, medication optimization, and faster access to therapy. Pharmacy teams can also use EHR-based searches and emerging AI tools to identify at-risk patients.<br /><br />Operationally, speakers discussed challenges and solutions for provider-administered medications, including benefits investigation, prior authorization, site-of-care selection, and infusion capacity. Centralized infusion and pharmacy services, buy-and-bill models, and strong revenue cycle coordination were presented as key enablers. Alnylam was noted as a partner in education, workflow design, access support, and patient identification strategies.

Keywords

transthyretin amyloidosis

ATTR cardiomyopathy

pharmacy-cardiology partnership

embedded clinical pharmacists

patient identification

EHR-based screening

AI risk stratification

prior authorization and benefits investigation

infusion services and buy-and-bill